Exploring 3 High Growth Tech Stocks In The US Market
In the last week, the United States market has stayed flat, yet it has risen 19% over the past year, with earnings expected to grow by 18% annually in the coming years. In such a dynamic environment, identifying high growth tech stocks can be key for investors seeking to capitalize on innovation and robust financial performance.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| AppLovin | 21.14% | 21.74% | ★★★★★★ |
| Krystal Biotech | 29.59% | 37.16% | ★★★★★★ |
| 21.90% | 25.36% | ★★★★★★ | |
| Fabrinet | 21.38% | 23.34% | ★★★★★★ |
| Sandisk | 46.24% | 46.18% | ★★★★★★ |
| Palantir Technologies | 30.88% | 31.93% | ★★★★★★ |
| Zscaler | 14.32% | 55.01% | ★★★★★☆ |
| KVH Industries | 28.67% | 146.09% | ★★★★★☆ |
| Duos Technologies Group | 61.81% | 48.23% | ★★★★★☆ |
| Circle Internet Group | 20.95% | 48.69% | ★★★★★☆ |
Click here to see the full list of 60 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
LightPath Technologies (LPTH)
Simply Wall St Growth Rating: ★★★★★☆
Overview: LightPath Technologies, Inc. is a company that focuses on the design, development, manufacturing, and distribution of optical systems and assemblies in the United States with a market capitalization of $737.15 million.
Operations: LightPath Technologies generates revenue primarily from its Optics Segment, which designs and manufactures products, contributing $62.77 million.
LightPath Technologies, recently added to several Russell indexes, demonstrates a significant market recognition which could enhance its visibility among institutional investors. Despite being unprofitable currently, the company's revenue growth is robust at 36.2% annually, outpacing the US market average of 13%. This growth is supported by a substantial increase in R&D spending aimed at innovation in optical solutions—a sector critical for advancements in high-tech industries. However, shareholder dilution and a volatile share price reflect ongoing financial challenges. The recent private placement of $10.8 million and follow-on equity offering raising nearly $100 million suggest strategic moves to stabilize finances while pursuing growth opportunities in burgeoning tech sectors like AI and telecommunications.
Rezolute (RZLT)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Rezolute, Inc. is a late-stage company dedicated to enhancing treatments for individuals with hypoglycemia due to hyperinsulinism in the United States, with a market cap of $496.22 million.
Operations: Rezolute, Inc. is focused on developing treatments for rare diseases, specifically targeting hypoglycemia due to hyperinsulinism. The company operates in the United States and is positioned as a late-stage development entity within the biotech sector.
Rezolute's recent presentations at ENDO 2026 underscore its commitment to addressing hyperinsulinism (HI) with its innovative therapy, ersodetug. The company reported a reduction in net loss from $18.91 million to $16.17 million year-over-year for the third quarter, indicating a positive trajectory amidst ongoing R&D efforts. These developments are pivotal as Rezolute advances ersodetug through Phase 3 trials, demonstrating significant potential in treating rare metabolic disorders with high unmet medical needs. This focus on specialized, high-stakes treatment aligns with broader trends in biotech towards targeted therapies, potentially positioning Rezolute well within this niche market despite current unprofitability.
- Click here and access our complete health analysis report to understand the dynamics of Rezolute.
Understand Rezolute's track record by examining our Past report.
Larimar Therapeutics (LRMR)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Larimar Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for rare diseases through its innovative cell penetrating peptide technology platform, with a market cap of $446.76 million.
Operations: The company is focused on developing treatments for rare diseases using its proprietary cell penetrating peptide technology platform. As a clinical-stage biotechnology firm, it does not currently generate revenue from product sales.
Larimar Therapeutics, recently added to several Russell growth indices, is navigating an ambitious path with its innovative treatment, nomlabofusp, for Friedreich’s ataxia—a rare neurological disorder. With revenue growth projected at 53.9% annually and earnings expected to surge by 52.48% per year, Larimar's strategic focus on R&D is evident as they push towards profitability within three years. The company's latest regulatory strides include a rolling BLA submission to the FDA, promising a robust pipeline that could set new standards in treatment efficacy and patient care in its segment.
- Delve into the full analysis health report here for a deeper understanding of Larimar Therapeutics.
Gain insights into Larimar Therapeutics' past trends and performance with our Past report.
Seize The Opportunity
- Get an in-depth perspective on all 60 US High Growth Tech and AI Stocks by using our screener here.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Want To Explore Some Alternatives?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com